Abstract

Breast cancer remains a leading cause of cancer morbidity and mortality worldwide, necessitating advances in risk 
stratification, early detection, and personalized treatment strategies. Spatial omics technologies encompassing 
spatial transcriptomics, proteomics, and histopathological profiling offer unprecedented insight into tumour 
architecture, microenvironmental interactions, and intratumoural heterogeneity. This study critically examines 
the clinical validity and utility of spatial omics in breast cancer, with particular attention to its implications for 
population screening and health policy. While spatial omics holds promise for improving diagnostic precision and 
identifying novel biomarkers, current evidence of clinical validity remains limited, with few studies demonstrating 
robust associations between spatial signatures and patient outcomes. The paper further evaluates the feasibility, 
accuracy, and equity considerations of integrating spatial omics into population screening programmes. Key 
challenges include high costs, limited accessibility, lack of standardization, and insufficient validation across 
diverse populations. From a policy perspective, the integration of spatial omics requires careful consideration of 
regulatory frameworks, ethical safeguards, data governance, and cost-effectiveness. The study argues that, 
although spatial omics represents a transformative advancement in cancer research, its translation into routine 
screening and clinical practice demands coordinated investment in validation studies, infrastructure, and equitable 
implementation strategies. Ultimately, spatial omics should be viewed as a complementary tool that augments 
existing screening paradigms rather than a standalone solution.